3-((tert-butoxycarbonyl)(phenyl)amino)propanoic acid | 121494-14-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-((tert-butoxycarbonyl)(phenyl)amino)propanoic acid
• 英文别名: 3-[N-[(2-methylpropan-2-yl)oxycarbonyl]anilino]propanoic acid
• CAS: 121494-14-2
• 化学式: C₁₄H₁₉NO₄
• 分子量: 265.309
• InChiKey: YSMMPLIVJMNIFC-UHFFFAOYSA-N

物化性质

• 沸点：
  399.8±25.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-((tert-butoxycarbonyl)(phenyl)amino)propanoic acid 在 盐酸 、 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 N-羟基-7-氮杂苯并三氮唑 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 2-bromo-N-[3-(N-(2-bromoacetyl)anilino)propyl]-N-[3-[(2-bromoacetyl)-[3-(N-(2-bromoacetyl)anilino)propyl]amino]propyl]acetamide
  参考文献：
  名称：

  Covalent Reinforcement of Hydrogen-Bonded Discs into Stably Folded Helical Structures

  摘要：

  The presence of covalent tethers significantly enhanced the stability of structures consisting of helically arranged benzenetricarboxamide units that otherwise undergo very weak hydrogen-bonding interaction. The resultant molecular structures were probed by computational study, which predicted folded conformations consisting of helically arranged discs. Experimental studies confirmed the H-bonding interaction between the disk units, the monomeric nature of the corresponding molecules in solution, and the helical conformations of such molecules.

  DOI：

  10.1021/ol201526g
• 作为产物：
  描述：

  3-(苯基氨基)丙酸甲酯 在 碳酸氢钠 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 3-((tert-butoxycarbonyl)(phenyl)amino)propanoic acid
  参考文献：
  名称：

  Covalent Reinforcement of Hydrogen-Bonded Discs into Stably Folded Helical Structures

  摘要：

  The presence of covalent tethers significantly enhanced the stability of structures consisting of helically arranged benzenetricarboxamide units that otherwise undergo very weak hydrogen-bonding interaction. The resultant molecular structures were probed by computational study, which predicted folded conformations consisting of helically arranged discs. Experimental studies confirmed the H-bonding interaction between the disk units, the monomeric nature of the corresponding molecules in solution, and the helical conformations of such molecules.

  DOI：

  10.1021/ol201526g
• 作为试剂：
  描述：

  3-((tert-butoxycarbonyl)(phenyl)amino)propanoic acid 、 2-(1,2,3,4-tetrahydro-2-isoquinolylcarbonyloxy)ethylamine 在 3-((tert-butoxycarbonyl)(phenyl)amino)propanoic acid 作用下， 以76.4的产率得到2-[3-[N-[(2-methylpropan-2-yl)oxycarbonyl]anilino]propanoylamino]ethyl 3,4-dihydro-1H-isoquinoline-2-carboxylate
  参考文献：
  名称：

  Pyridinium nitrate, composition containing same and their use for

  摘要：

  公式为##STR1##的新化合物是一种血小板活化因子拮抗剂，其稳定性优越，因此可用作药物。

  公开号：

  US04981860A1

文献信息

• [EN] HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS<br/>[FR] HÉTÉROARYL-CARBOXAMIDES COMME INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：ORYZON GENOMICS SA

  公开号：WO2018219478A1

  公开（公告）日：2018-12-06

  The invention relates to heteroaryl-carboxamides as described herein, useful as histone demethyiase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

  本发明涉及如本文所述的杂环基-羧酰胺，其作为组蛋白去甲基酶抑制剂具有用处。本发明还涉及包含这些化合物的药物组合物，以及它们在治疗中的应用，包括例如在癌症治疗中的应用。
• [EN] HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS<br/>[FR] ACIDES HÉTÉROARYL-CARBOXYLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：ORYZON GENOMICS SA

  公开号：WO2017207813A1

  公开（公告）日：2017-12-07

  The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

  该发明涉及异芳基羧酸，如本文所述，作为组蛋白去甲基化酶抑制剂。该发明还涉及包含这些化合物的药物组合物，以及它们在治疗中的应用，例如用于癌症治疗。
• Decarboxylative Intramolecular Arene Alkylation Using <i>N</i>-(Acyloxy)phthalimides, an Organic Photocatalyst, and Visible Light
  作者：Trevor C. Sherwood、Hai-Yun Xiao、Roshan G. Bhaskar、Eric M. Simmons、Serge Zaretsky、Martin P. Rauch、Robert R. Knowles、T. G. Murali Dhar

  DOI：10.1021/acs.joc.9b00432

  日期：2019.7.5

  An intramolecular arene alkylation reaction has been developed using the organic photocatalyst 4CzIPN, visible light, and N-(acyloxy)phthalimides as radical precursors. Reaction conditions were optimized via high-throughput experimentation, and electron-rich and electron-deficient arenes and heteroarenes are viable reaction substrates. This reaction enables access to a diverse set of fused, partially

  使用有机光催化剂4CzIPN，可见光和N-（酰氧基）邻苯二甲酰亚胺作为自由基前体，已经开发出分子内芳烃烷基化反应。通过高通量实验优化了反应条件，富电子和缺电子的芳烃和杂芳烃是可行的反应底物。该反应使得能够获得各种各样的熔融的，部分饱和的核，这些核在合成和药物化学中具有很高的意义。
• Pyridinium derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd

  公开号：US04962113A1

  公开（公告）日：1990-10-09

  Novel pyridinium derivatives represented by the formula (I): ##STR1## wherein ##STR2## is an optionally substituted pyridinium ring; R.sup.1 is a lower alkyl group or aralkyl group; R.sup.7 and R.sup.10 are independently hydrogen, a lower alkyl group, aryl group or aralkyl group; l is 0 or 1; R.sup.5 is a phenylene group or an alkylene group which may be substituted; R.sup.11 is an alkyl group or aryl group; X is a group of the formula: --CH.sub.2 OCH.sub.2 -- or a group of the formula: ##STR3## wherein R.sup.6 is hydrogen, a lower alkyl or a lower alkoxy, and m is an integer of 0 to 3; U is a group of the formula: ##STR4## wherein R.sup.4 is hydrogen, a lower alkyl group, aryl group or aralkyl group; Y and Z are independently a divalent chain group consisting of one to six members which is selected from the class consisting of groups of the formulae: ##STR5## wherein R is hydrogen, a lower alkyl group, acyl group or aryl group and at least one of which is a group of the formula: ##STR6## with the proviso that R may be the same or different from each other, or may form a ring together when two or more groups of the formula: ##STR7## are present, that R may be bonded to R.sup.4 when Y contains a group of the formula: ##STR8## and that R may be bonded to R.sup.11 when Z contains a group of the formula: ##STR9## and W.sup..crclbar. is a counter anion; are useful as a platelet activating factor antagonist.

  新型吡啶盐衍生物的结构如下（I）：##STR1##其中##STR2##是一个可选择取代的吡啶环；R.sup.1是一个低碳烷基或芳基烷基；R.sup.7和R.sup.10独立地是氢、低碳烷基、芳基或芳基烷基；l为0或1；R.sup.5是一个苯基或可能被取代的烷基；R.sup.11是一个烷基或芳基；X是一个式子：--CH.sub.2 OCH.sub.2 --或一个式子：##STR3##其中R.sup.6是氢、低碳烷基或低烷氧基，m是0到3的整数；U是一个式子：##STR4##其中R.sup.4是氢、低碳烷基、芳基或芳基烷基；Y和Z独立地是由1到6个成员组成的二价链状基团，选自下列式：##STR5##其中R是氢、低碳烷基、酰基或芳基，至少有一个是下列式之一：##STR6##但要求R可以相同也可以不同，或者当存在两个或更多的下列式之一：##STR7##时，R可以一起形成环；当Y包含一个下列式之一：##STR8##时，R可以与R.sup.4结合；当Z包含一个下列式之一：##STR9##时，R可以与R.sup.11结合；W.sup..crclbar.是一个反离子；这些化合物可用作血小板活化因子拮抗剂。
• Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an <i>aza</i> ‐decaline scaffold
  作者：Kenta Teruya、Yasunao Hattori、Yasuhiro Shimamoto、Kazuya Kobayashi、Akira Sanjoh、Atsushi Nakagawa、Eiki Yamashita、Kenichi Akaji

  DOI：10.1002/bip.22773

  日期：2016.7

  substantial contribution of this side chain (∼10%) for the explanation of pIC50s was dependent on stereochemistry and the chemical structure of the ligand adapted to the S2 pocket of the protease. Thus, starting from a substrate mimic inhibitor, a design for a central scaffold for a low molecular weight inhibitor was evaluated to develop a further potent inhibitor. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept

  设计针对严重急性呼吸系统综合症（SARS）胰凝乳蛋白酶样蛋白酶（3CL pro）的抑制剂是对抗SARS的潜在重要方法。我们已经通过基于结构的药物设计开发了几种合成抑制剂。在本报告中，基于我们以前的工作，我们揭示了SARS 3CL pro的两种晶体结构与两种新抑制剂的复合作用。这些结构与六个晶体结构相结合，这些晶体结构与我们报道的一系列相关配体复合在一起，得到了共同分析。对于这八种复合物，通过COMBINE方法分析了抑制剂结合的结构基础，该方法是针对蛋白质-配体复合物进行优化的化学计量分析。分析显示，前两个潜在变量的累计贡献率为r2  = 0.971。有趣的是，使用每个复合物的第二个潜在变量的得分与Met 49的侧链重原子与SARS-3CL pro完整晶体结构的均方根偏差（RMS = 0.77）紧密相关（r = 0.77）。 S 2口袋。该侧链对解释pIC 50 s的实质贡献（约10％）取决于立体化学和适应S